GLP-1 / GIP Agonists
Tirzepatide 30mg
A dual GLP-1 and GIP receptor agonist studied for metabolic regulation and glucose homeostasis.
Form
Lyophilized Powder
Quantity
30mg per vial
Purity
>99% (HPLC)
Sequence
39aa GLP-1/GIP agonist
MW
4,813 g/mol
Storage
-20°C (lyophilized)
Batch Verification
Purity (HPLC)
>99%
Batch ID
VX-TIRZ30-001
MW Confirmed
LC-MS
Endotoxin
<0.1 EU/mg
Independently verified by Janoshik: HPLC Purity + LC-MS Identity + LAL Endotoxin
Research Applications
Tirzepatide is a synthetic 39-amino-acid peptide agonist of glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor.
Research applications:
- Dual incretin receptor pharmacology
- GPCR signaling pathway investigation
- Beta-arrestin recruitment studies
- cAMP/PKA pathway analysis
Research explores binding affinity for human GIP receptor (Ki ~0.35 nM) and GLP-1R (Ki ~0.7 nM) in recombinant cell systems.
Research Use Only
This product is intended for laboratory research use only. Not for human consumption or clinical use. Not FDA approved for diagnostic or therapeutic purposes.
This product is intended for laboratory research use only. Not for human consumption or clinical use. Not FDA approved for diagnostic or therapeutic purposes.